Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
45 hedge funds and large institutions have $42.9M invested in Viracta Therapeutics, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 4 reducing their positions, and 7 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 4
178% more call options, than puts
Call options by funds: $1.18M | Put options by funds: $424K
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
47% more capital invested
Capital invested by funds: $29.1M → $42.9M (+$13.8M)
13% more funds holding
Funds holding: 40 → 45 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$4.51M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.98M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$2.63M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$2.09M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
-$583K |
| 2 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$97K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$72K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$69.3K |
| 5 |
NFG
Noven Financial Group
Denver,
Colorado
|
-$23K |
VIRX Hedge Fund Activity: Q4 2016 in Review
45 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2016, worth a combined $42.9M — up 47% from $29.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new VIRX positions and 7 closed out — a net gain of 5 holders — while 14 added to existing stakes and 4 trimmed.
The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $4.51M. The largest seller was Frontier Wealth Management, exiting entirely with an estimated $583K sold.
- 45 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2016, up from 40 in Q3 2016.
- Funds reported $42.9M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2016, up 47% quarter-over-quarter.
- 12 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2016 and 7 closed out, a net change of +5 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2016 was DAFNA Capital Management, an estimated $4.51M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2016 was Frontier Wealth Management, an estimated $583K sold.
Based on aggregated 13F filings for Q4 2016.